Dr. James Helliwell reports

EUPRAXIA PHARMACEUTICALS STRENGTHENS EXECUTIVE LEADERSHIP TEAM TO SUPPORT NEXT PHASE OF GROWTH

Eupraxia Pharmaceuticals Inc. has made updates to its executive leadership and operating structure as the company continues to prepare for its next stage of clinical and commercial development.

Dr. Jeff Millard has joined Eupraxia as executive vice-president, technical operations, effective July 13, 2026. Dr. Millard brings nearly 25 years of leadership experience in technical operations, CMC and regulatory strategy, having held senior leadership positions at Ensysce Biosciences, Microbion Corp. and Cascadian Therapeutics, where he advanced product candidates from discovery through commercialization. Dr. Millard will be leading these critical functions for Eupraxia, where his deep experience in the transition from development to commercialization and his history of operational excellence will be foundational to the success of EP104GI.

As part of these changes, Dr. Alex Therien, who joined Eupraxia in November, 2025, will take the helm of research and development in his role as executive vice-president, research and development. Dr. Therien brings more than 20 years of biopharmaceutical leadership experience, having held senior research and development leadership positions at Generate Biomedicines, Eikon Therapeutics and Merck, and is well suited to drive portfolio expansion at Eupraxia.

"Eupraxia is looking to its Q4 2026 Resolve trial interim release in eosinophilic esophagitis (EOE) as a key catalyst for the growth of the company and its GI portfolio expansion. As we prepare for this on the back of positive data in the phase 2a Resolve trial, it has been critical to ensure the company is ready to tackle the phase 3 development, regulatory, manufacturing and commercialization preparations. To this end, the recently announced addition of deeply experienced directors and these executive leaders announced today signal the shift from an early-stage company to a late-stage one with experienced leaders to shepherd this pivotal growth stage," said Dr. James Helliwell, chief executive officer of Eupraxia.

As Eupraxia evolves into a cross-border two-hub organization, Eupraxia has completed the transition of its operations from Victoria to Vancouver and Seattle, reflecting the company's focus on supporting its growing clinical operations. Key clinical, manufacturing and commercial executive leadership positions, including the CEO, will be based in the Seattle offices.

As part of this transition, Amanda Malone, based in Victoria, has stepped down from her role as chief scientific and operating officer, effective July 10, 2026. Eupraxia is grateful for her years of expertise in research and early-stage development.

About Eupraxia Pharmaceuticals Inc.

Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Diffusphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology is designed to support extended duration of effect and delivery of drugs in a hyperlocalized fashion, targeting only the tissues that physicians are wanting to treat. The company believes the potential for fewer adverse events may be achieved through the precision targeting and the stable and flat delivery of the active ingredient when using the Diffusphere technology, versus the peaks and troughs seen with more traditional drug delivery methods. The precision of Eupraxia's Diffusphere technology platform has the potential to augment and transform existing FDA-approved (U.S. Food and Drug Administration) drugs to improve their safety, tolerability, efficacy and duration of effect. The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestinal disease, where Eupraxia currently is developing advanced treatments, to also be applicable in oncology, infectious disease and other critical disease areas.

Eupraxia's EP-104GI is currently in a phase 1b/2 trial, the Resolve trial, for the treatment of EoE. EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. This is a unique treatment approach for EoE. Eupraxia also completed a phase 2b clinical trial (Springboard) of EP-104IAR for the treatment of pain due to knee osteoarthritis. The trial met its primary end point and three of the four secondary endpoints. In addition, Eupraxia is developing a pipeline of later and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other inflammatory joint indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs.

We seek Safe Harbor.